

FOR LAB USE ONLY

			,
MOLECULAR DIAGNOSTIC REQUEST FORM		CAMPLE INFORMATION	
PATIENT INFORMATION		SAMPLE INFORMATION	
NAME: FIRST NAME ID/PASSPORT NO: DATE OF E		DATE OF COLLECTION:/_ DD SAMPLE TYPE (Please select one): Blood, Specify (EDTA, clotted) Paraffin Embedded Tissue (FFPE) EDTA Plasma Serum Body Fluid, Specify Type: Swab, Specify Type:	Nasopharyngeal Aspirate/Swab Autocyte/ThinPrep
CLINICAL DIAGNOSIS: GENDER FEMALE MALE		Tissue,Specify Type: Other,Please Specify:	
PATIENT CONSENT		REPORT INFORMATION	
Confirmation of patient informed consent for genetic testing		PHYSICIAN: INSTITUTION: PHONE: SIGNATURE:	FAX:DATE(DD/MM/YY):
Please put a "✓	" in the box(es) to i	indicate the test(s) to be p	erformed.
Oncology Testing		Oncology Testing (Cont.)	
□ GAIA ^{@MPD} NGS Panel □ LUNG ^{@MPD} NGS Panel □ cfLUNG ^{@MPD} NGS Panel □ COLON ^{@MPD} NGS Panel □ cfBREAST ^{@MPD} NGS Panel □ ACTION ^{@MPD} NGS Panel		 □ PIK3CA Gene Hotspot Mutation Detection (exon 10 & 21) □ PIK3CA Gene Hotspot Mutation Detection [Extended] (exon 2, 3, 5, 8, 10 & 21) □ POLE Gene Hotspot Mutation Detection (exon 9-14) □ RET Gene Rearrangement Detection by FISH □ RET Gene Hotspot Mutation Detection (exon 5, 8, 10, 11, 13-16) □ ROS1 Gene Rearrangement Detection by FISH □ TERT Gene Promoter Mutation Detection 	
☐ Brain Cancer Panel (MGMT Promoter Methylation & Chromosome 1p/19q Deletion)		Foundation Medicine / Oncotype	
☐ BRCA1 & BRCA2 Gene Comprehensive Study ☐ Breast Immunohistochemistry Panel (ER, PR, HER2 & Ki-67)		FOUNDATIONONE CDx (324 cancer-related genes)	
□ Endometrial Adenocarcinoma Classification Panel (POLE, MMR IHC & p53 IHC) □ IDH1 & IDH2 Gene Mutation Detection □ KIT & PDGFRA Gene Mutation Detection		 □ FOUNDATIONONE LIQUID CDx (311 cancer-related genes) □ FOUNDATIONONE HEME Tissue (406 (DNA) & 265 (RNA) cancer-related genes) □ Oncotype DX Breast Recurrence Score test 	
KRAS & NRAS Gene Mutation Detection		Use ditant Consul Security	
□ Lung Cancer Panel I (EGFR, ALK FISH & ROS1 FISH) □ Lung Cancer Panel II (BRAF, MET ex.14 skipping & ERBB2 ex.20)		Hereditary Cancer Screening	
Lung Cancer Panel III (EGFR, ALK IHC & ROS1 FISH) MAP2K1 (MEK1) & MAP2K2 (MEK2) Gene Mutation Detection Microsatellite Instability Test & MMR Immunohistochemistry AKT1 codon 17 Mutation Detection ALK Gene Rearrangement Detection by FISH		 □ APC Gene Comprehensive Study □ BRCA1 & BRCA2 Gene Comprehensive Study □ BMPR1A Gene Comprehensive Study □ CDH1 Gene Mutation Detection □ CHEK2 1100delC Mutation Detection □ EPCAM Gene Deletion Study 	
□ BRAF codon V600 Mutation Detection		☐ MLH1 Gene Comprehensive Study	
□ CDKN2A/B Homozygous Deletion Detection by FISH □ Chromosome 1p/19q Deletion by FISH □ EGFR Gene Hotspot Mutation Detection (exon 18-21) □ EGFR Gene Amplification Detection by FISH		 ☐ MMR Genes Promoter Methylation Detection ☐ MSH2 Gene Comprehensive Study ☐ MSH6 Gene Comprehensive Study ☐ MUTYH Gene Comprehensive Study 	
☐ ERBB2 exon 20 Mutation Detection		□ PMS2 Gene Comprehensive Study	
□ ERBB2 (HER2) Gene Amplification by FISH Fixation time □<6 hrs □ 6-72 hrs □>72 hrs □ ERBB2 (HER2) Immunohistochemistry □ ESR1 Gene Hotspot Mutation Detection (exon 5, 7 & 8) □ Histone 3 K27 / G34 Mutation Detection		 □ PTEN Gene Comprehensive Study □ RET Gene Hotspot Mutation Detection □ SLC25A13 Gene Mutation Detection □ STK11 Gene Comprehensive Study 	
☐ HRAS Gene Hotspot Mutation Detection (exon 2-4)		☐ SMAD4 Gene Comprehensive Study	
 □ HPV Detection and Genotyping (37 Genotypes) for FFPE □ KIT Gene Hotspot Mutation Detection (exon 9, 11, 13, 14 & 17) □ KRAS Gene Hotspot Mutation Detection (exon 2-4) □ MAPK1 E322K Mutation Detection 		 □ TP53 Gene Comprehensive Study □ VHL Gene Comprehensive Study □ Specific Gene Known Mutation Screening (Point Mutation, Small Deletion and Insertion) □ Hereditary Cancer Panel (84 cancer-related genes) 	
☐ MET exon 14 Skipping Mutation Detection		Pharmacogenomics CVP2C0 & VKOPC1 Conctaining for Warfarin Treatment	
☐ MET Gene Amplification Detection by FISH		☐ CYP2C9 & VKORC1 Genotyping for Warfarin Treatment ☐ CYP2C19 Genotyping for Clopidogrel Treatment	
☐ MGMT Promoter Methylation by Methylation Specific PCR		DPYD Genotyping for 5-FU Responsiveness	
☐ Microsatellite Instability Test		☐ HLA-B*1301 Genotyping for Dapsone, Baktar or Phenytoin Treatment	
MMR Immunohistochemistry		☐ HLA-B*1502 Genotyping for Carbamazepine Treatment	
□ NRAS Gene Hotspot Mutation Detection (exon 2-4)		HLA-B27 Genotyping	
p53 Immunohistochemistry		HLA-B*5801 Genotyping for Allopurino Treatment	

Others Please Specify:



TPMT Genotyping for Thiopurine Drugs Treatment

UGT1A1 Genotyping for Irinotecan Toxicity

PDGFRA Gene Hotspot Mutation Detection (exon 12 & 18)

PDL1 Immunohistochemistry 22C3 28-8 SP263 SP142